2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5822 Longitudinal MRD kinetics refine clinical risk stratification through quantitative and qualitative evolution of residual disease in newly diagnosed multiple myeloma

Evangelos Terpos, MD, Panagiotis Malandrakis, MD, MSc, PhD2, Ioannis V Kostopoulos, PhD, MSc3, Ioannis Ntanasis-Stathopoulos, MD4, Pantelis Rousakis5, Nikolaos Tsakirakis6, Evangelos Eleutherakis-Papaiakovou7, Nikolaos Angelis8, Chrysanthi Panteli9, Panagiotis Bakouros10, Eirini Solia, MD11, Ilias Katsadouros, MD12, Georgia Dimitrakopoulou13, Panagiotis Boutsikos, MD14, Magdalini Migkou15, Nikolaos Kanellias, MD, PhD16, Maria Gavriatopoulou, MD17, Efstathios Kastritis, MD18, Ourania Tsitsilonis, MD,PhD19, Meletios-Athanasios (Thanos) C. Dimopoulos, MD20
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece
17 National and Kapodistrian University of Athens, Athens, Greece
18 National and Kapodistrian University of Athens, Athens, Greece
19 National and Kapodistrian University of Athens, Athens, Greece
20 National and Kapodistrian University of Athens, Athens, Greece

Background:
Minimal residual disease (MRD) is one of the strongest prognostic biomarkers in multiple myeloma (MM). However, MRD represents a dynamic process, and a single assessment may not adequately capture the evolution of residual disease. We investigated whether longitudinal MRD kinetics, together with quantitative and qualitative changes of residual disease, provide additional prognostic information in newly diagnosed MM (NDMM).

Aims:
To evaluate the prognostic significance of longitudinal MRD kinetics and determine whether quantitative changes in MRD burden, clonal evolution, and bone marrow (BM) immune microenvironment remodeling further refine clinical outcome.

Methods:
We retrospectively analyzed 385 NDMM patients who underwent more than 2254 serial MRD assessments by next-generation flow cytometry (NGF), with each patient contributing at least three consecutive MRD evaluations. Patients were classified according to longitudinal MRD kinetics into four predefined groups: sustained MRD negativity (sMRDneg), sustained MRD positivity (sMRDpos), conversion from MRD positivity to negativity (cMRDneg), and conversion from MRD negativity to positivity (cMRDpos). Progression-free survival (PFS) was compared among MRD kinetic groups. Consecutive MRD-positive assessments were further analyzed for quantitative changes in MRD burden and evidence of clonal evolution, defined by immunophenotypic changes and/or shifts in the relative distribution of residual plasma-cell subpopulations. Longitudinal BM immune profiling was performed to characterize changes accompanying MRD resurgence.

Results:
After a median follow-up of 6.1 years, patients underwent a median of five MRD assessments (range, 3–14). Overall, 219 (57%) patients remained persistently MRD-negative, 46 (12%) remained persistently MRD-positive, 61 (16%) converted from MRD positivity to negativity, and 59 (15%) converted from MRD negativity to positivity.

Longitudinal MRD kinetics significantly discriminated clinical outcome. Compared with sustained MRD negativity, sustained MRD positivity was associated with inferior PFS (HR=4.84, 95%CI 1.91–12.30; P<0.001), while conversion from MRD negativity to positivity identified patients with the highest risk of progression (HR=6.04, 95%CI 2.74–13.31; P<0.001). Moreover, the occurrence of even a single MRD-positive assessment during follow-up was associated with significantly inferior PFS compared with sustained MRD negativity (HR=4.29, 95%CI 2.05–8.99; P<0.001).

Among patients with consecutive MRD-positive assessments, longitudinal evaluation of MRD burden further refined risk stratification. Patients demonstrating a progressive increase in MRD burden experienced the poorest clinical outcome compared with those maintaining stable MRD levels despite persistent positivity (median PFS, 13 vs 45 months; HR=0.36, 95%CI 0.17–0.75). Furthermore, approximately 15% of patients with consecutive MRD-positive assessments exhibited evidence of clonal evolution, defined by immunophenotypic changes and/or changes in the relative distribution of residual plasma-cell subpopulations, which was associated with inferior clinical outcome (P=0.04).

Conversion from MRD negativity to MRD positivity was accompanied by significant remodeling of the BM immune microenvironment, characterized by an increase in NK-cell representation (median 3.2% to 4.7%; P=0.0033) and in the memory-to-naïve B-cell ratio (median 0.4 to 1.4; P<0.0001), supporting the biological relevance of longitudinal MRD evolution.

Conclusions:
Longitudinal MRD kinetics provide clinically meaningful prognostic information beyond a single MRD assessment in NDMM. In addition to established MRD kinetic patterns, progressive increase in MRD burden and evidence of clonal evolution identify subsets of persistently MRD-positive patients with particularly adverse clinical outcome. The accompanying remodeling of the BM immune microenvironment during conversion from MRD negativity to MRD positivity further supports that longitudinal MRD assessment captures the dynamic biological evolution of residual disease. These findings support the incorporation of sequential MRD monitoring into future MRD-guided risk stratification strategies.

Evangelos Terpos, MD: Swixx - Honoraria; Takeda - Honoraria; Menarini - Honoraria; Johnson & Johnson - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Antengene - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; EUSA Pharma - Honoraria; Johnson & Johnson - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Menarini - Research Funding; Menarini - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)